Maintenance phase treatment of psychotic disorders in outpatients from Serbia – focus on long-term benzodiazepine use

References

• Al Khaja KAJ, Al-Haddad MK, Sequeira RP, Al-Offi AR. 2012. Antipsychotic and anticholinergic drug prescribing pattern in psychiatry: extent of evidence-based practice in Bahrain. PP. 03(04):409–416. doi:10.4236/pp.2012.34055
   Google Scholar
• Anthierens S, Habraken H, Petrovic M, Christiaens T. 2007. The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitetive study on GPs’ perspectives. Scand J Prim Health Care. 25(4):214–219. doi:10.1080/02813430701726335
   PubMed Web of Science ®Google Scholar
• Barbui C, Saraceno B, Liberati A, Garattini S. 1996. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. Eur Psychiatry. 11(6):306–313. doi:10.1016/S0924-9338(96)89899-3
   PubMed Web of Science ®Google Scholar
• Barnes TR, Paton C. 2011. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 25(5):383–399. doi:10.2165/11587810-000000000-00000
   PubMed Web of Science ®Google Scholar
• Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. 1994. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med. 24(2):307–316. doi:10.1017/S003329170002729X
   PubMed Web of Science ®Google Scholar
• Cetin M. 2014. A serious risk: excessive and inappropriate antipsychotic prescribing. Klinik Psikofarmakoloji Bulteni. 24(1):1–4. doi:10.5455/bcp.20140314014626
   Google Scholar
• Covell NH, Jackson CT, Evans AC, Essock SM. 2002. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 28(1):17–29. doi:10.1093/oxfordjournals.schbul.a006920
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Uchida H. 2014. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 17(7):1083–1093. doi:10.1017/S1461145712000399
   PubMed Web of Science ®Google Scholar
• Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, Lehrer D, Klein R, Hurst M. 2016. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry. 77(05):661–667. doi:10.4088/JCP.15m10271
   PubMedGoogle Scholar
• Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, De Pablo J, Vilella E. 2015. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish province of Tarragona. PLoS One. 10(10):e0139403. doi:10.1371/journal.pone.0139403
   PubMed Web of Science ®Google Scholar
• Gillies D, Beck A, McCloud A. 2001. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev. 4:CD003079.
   Google Scholar
• Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller H-J, WFSBP Task force on Treatment Guidelines for Schizophrenia. 2013. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 14(1):2–44. doi:10.3109/15622975.2012.739708
   PubMed Web of Science ®Google Scholar
• Howes O, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. 2009. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 15(22):2550–2559. doi:10.2174/138161209788957528
   PubMed Web of Science ®Google Scholar
• Keetharuth AD, Brazier J, Connell J, Bjorner JB, Carlton J, Taylor Buck E, Ricketts T, McKendrick K, Browne J, Croudace T. 2018. Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. Br J Psychiatry. 212(1):42–49. doi:10.1192/bjp.2017.10
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee HW, Jung SH, Kang MH, Bae JN, Lee JS, Kim CE. 2014. Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy. Clin Psychopharmacol Neurosci. 12(2):128–136. doi:10.9758/cpn.2014.12.2.128
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. 2006. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 84(1):90–99. doi:10.1016/j.schres.2006.02.023
   PubMed Web of Science ®Google Scholar
• Lečić-Tosevski D (Ed.). 2013. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje shizofrenije. Republička stručna komisija za izradu i implementaciju vodiča u kliničkoj praksi. Beograd: Ministarstvo zdravlja Republike Srbije, Serbian).
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Askland K. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S, Kissling W, Davis JM. 2012. Evidence-based pharmacotherapy of schizophrenia. In: Stein D, Lerer B, Stahl SM, editors. Essential evidence-based psychopharmacology. 2nd ed. Cambridge: Cambridge University Press; p. 18–38.
   Google Scholar
• Leucht S, Samara M, Heres S, Davis JM. 2016. Dose equivalents for antipsychotic drugs: the DDD method. SCHBUL. 42(suppl 1):S90–S94. doi:10.1093/schbul/sbv167
   Google Scholar
• Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. 2002. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 1:CD001950.
   Google Scholar
• Longo LP, Johnson B. 2000. Addiction: part I. Benzodiazepines – side effects, abuse risk and alternatives. Am Fam Physician. 61(7):2121–2128.
   PubMed Web of Science ®Google Scholar
• Maric NP, Latas M, Andric Petrovic S, Soldatovic I, Arsova S, Crnkovic D, Gugleta D, Ivezic A, Janjic V, Karlovic D. 2017. Prescribing practices in Southeastern Europe – focus on benzodiazepine prescription at discharge from nine university psychiatric hospitals. Psychiatry Res. 258:59–65. doi:10.1016/j.psychres.2017.09.059
   PubMed Web of Science ®Google Scholar
• Maric NP, Pavlovic Z, Jasovic-Gasic M. 2011. Changes in antipsychotic prescription practice at University Hospital in Belgrade, Serbia: 2009 vs. 2004. Acta Psychiatr Scand. 123(6):495–495. doi:10.1111/j.1600-0447.2011.01690.x
   PubMed Web of Science ®Google Scholar
• Ministry of Health Singapore. 2008. MOH Clinical Practice Guidelines 2/2008. Prescribing of benzodiazepines. https://www.moh.gov.sg/docs/librariesprovider4/guidelines/cpg_prescribing-of-benzodiazepines.pdf
   Google Scholar
• Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep. 10(3):799–812. doi:10.2466/pr0.1962.10.3.799
   Web of Science ®Google Scholar
• Royal College of Psychiatrists. 2014. Consensus statement on high-dose antipsychotic medication. London: Royal College of Psychiatrists; p. 1–53.
   Google Scholar
• Sadock BJ, Sadock VA, Kaplan HI. 2003. Kaplan & Sadocks’ synopsis of Psychiatry: behavioral sciences/clinical psychiatry. Philadelphia: Lippincott Williams & Wilkins.
   Google Scholar
• Sun FF, Stock EM, Copeland LA, Zeber JE, Ahmedani BK, Morissette SB. 2014. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am J Heal Pharm. 71(9):728–738. doi:10.2146/ajhp130471
   PubMed Web of Science ®Google Scholar
• Taylor D, Barnes TRE, Young AH. 2018. The Maudsley prescribing guidelines in psychiatry. 13th ed. Newark: John Wiley & Sons.
   Google Scholar
• Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. 2012. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 69(5):476–483. doi:10.1001/archgenpsychiatry.2011.1532
   PubMed Web of Science ®Google Scholar
• Vares M, Saetre P, Stralin P, Levander S, Lindström E, Jönsson EG. 2011. Concomitant medication of psychoses in a lifetime perspective. Hum Psychopharmacol Clin Exp. 26(4–5):322–331. doi:10.1002/hup.1209
   PubMed Web of Science ®Google Scholar
• Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA. 2000. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 97(2–3):129–135. doi:10.1016/S0165-1781(00)00228-6
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. 2009. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 166(9):1055–1062. doi:10.1176/appi.ajp.2009.09010017
   PubMed Web of Science ®Google Scholar
• Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. 2009. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry. 42(2):66–71. doi:10.1055/s-0028-1103293
   PubMed Web of Science ®Google Scholar
• WHO Programme on Substance Abuse. 1996. Rational use of benzodiazepines. World Health Organization. https://apps.who.int/iris/handle/10665/65947
   Google Scholar
• Williams EO, Stock EM, Zeber JE, Copeland LA, Palumbo FB, Stuart M, Miller NA. 2012. Payer types associated with antipsychotic polypharmacy in an ambulatory care setting. J Pharm Heal Serv Res. 3(3):149–155. doi:10.1111/j.1759-8893.2012.00083.x
   Google Scholar
• Winkler P, Krupchanka D, Roberts T, Kondratova L, Machů V, Höschl C, Sartorius N, Van Voren R, Aizberg O, Bitter I, et al. 2017. A blind spot on the global mental health map: a scoping review of 25 years’ development of mental health care for people with severe mental illnesses in central and eastern Europe. Lancet Psychiatry. 4(8):634–642. doi:10.1016/S2215-0366(17)30135-9
   PubMed Web of Science ®Google Scholar
• Zink M, Englisch S, Meyer-Lindenberg A. 2010. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 23(2):103–111. doi:10.1097/YCO.0b013e3283366427
   PubMed Web of Science ®Google Scholar
• Zitman FG, Couvée JE. 2001. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group . Br J Psychiatry. 178:317–324. doi:10.1192/bjp.178.4.317
   PubMed Web of Science ®Google Scholar